EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03857-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Lingzhan Meng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Hepatobiliary Surgery Center, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Capital’s Funds for Health Improvement and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regimen of anti-PD-1/L1 inhibitor plus lenvatinib. This study aims to assess the efficacy and safety of TACE combined with lenvatinib and sintilimab in unresectable HCC patients. METHODS: Unresectable HCC patients who received TACE in combination with sintilimab plus Lenvatinib as first-line treatment from 1 January 2020 to 31 March 2023 were included for the analysis. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were evaluated by modified Response Evaluation Criteria in Solid Tumors criteria. Exploratory biomarker analysis was conducted. RESULTS: The study included 70 patients with unresectable HCC, predominantly male and infected with Hepatitis B. The median follow-up duration for the whole cohort was 13.8 months (95% CI 11.08-16.7). The ORR was 61.4% (95% CI, 49.0%-72.8%) and the DCR was 68.6% (95%CI, 56.4%-79.2%). The median PFS was 13.2 months (95% CI 11.0-NA), with a corresponding 1-year PFS rate of 50.3% (95% CI 39.7%-65.5%). The median OS was not reached, and the 1-year OS rate was 89.3% (95% CI 81.4%-97.9%). The most common treatment-related adverse events (TRAEs) were fatigue 38.6% (27/70), hypertension 32.9% (23/70), and hand-foot syndrome 31.4% (22/70). Most TRAEs were mild-to-moderate and manageable. In addition, significant predictive value was found in alpha-fetoprotein levels (AFP), with patients showing a level of decrease post-treatment having better PFS. CONCLUSION: The combination regimen demonstrated promising efficacy in treating unresectable HCC, accompanied by manageable safety profiles. Furthermore, the results of this investigation suggest that AFP holds promise as predictive biomarkers for this treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesChemoembolization, TherapeuticPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesCombined Modality TherapyFollow-Up Studies

Stichwörter der Autor:innen

Combination therapyHepatocellular carcinomaLenvatinibSintilimabTransarterial chemoembolization (TACE)

Substanzen

lenvatinibQuinolinesPhenylurea CompoundssintilimabAntibodies, Monoclonal, HumanizedBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Hepatobiliary Surgery Center, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, China.
  • Department of Geriatric Medicine, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, China.
  • Department of Hepatobiliary Surgery, The Third Medical Center of PLA General Hospital, Beijing, 100039, China.
  • Department of Liver Disease, The Fifth Medical Center of PLA General Hospital, No.100 Xi Si Huan Middle Road, Fengtai District, Beijing, 100039, China. gaoyj302@163.com.
  • Department of Hepatobiliary Surgery, Hepatobiliary Surgery Center, The Fifth Medical Center of PLA General Hospital, Beijing, 100039, China. zhuzy302@163.com.

Förderung

  • National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research
  • Capital’s Funds for Health Improvement and Research

Zitieren

APA

Meng, L., Li, H., Ji, Y., Yu, P., Wang, Z., Cao, L., Shi, B., Shao, Y., Yan, J., Gao, Y., & Zhu, Z. (2024). Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03857-5

Vancouver

Meng L, Li H, Ji Y, Yu P, Wang Z, Cao L, et al. Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03857-5

BibTeX
@article{Meng2024,
  author = {Meng, Lingzhan and Li, Hu and Ji, Yingjie and Yu, Peng and Wang, Zizheng and Cao, Li and Shi, Bin and Shao, Yanling and Yan, Jin and Gao, Yinjie and Zhu, Zhenyu},
  title = {Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03857-5}
}
Kostenlos starten →